This Week in Biotech

An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharma...

This Week in Biotech

Clinical data and buyout news whipsawed these five names in the biotech sector this week.

These Underdogs Are No Dogs

Like the smart hedge fund operators, these CAPS investors bet against a stock -- and won big!

5 Deathbed Stocks

Are investors hearing death rattles from these wounded companies?

The Exubera Winner

Who benefits from this failed inhaled-insulin product?

Nektar Squeezes Itself

Nektar Therapeutics cuts costs after a slower rollout of its lead compound.

Sour Results for Nektar

Nektar Therapeutics announces its first-quarter financial results and plans for the future.

Nektar Worth Waiting For?

Investors might be getting impatient, but the new insulin the company makes is special.